Newsummit Biopharma

MRC Technology licenses antibody to Newsummit Biopharma for hepatitis C

Tuesday, March 14, 2017

MRC Technology, a medical research charity, has licensed an antibody to Newsummit Biopharma, a China-based drug development process solutions provider, for development of a novel therapeutic for treatment of Hepatitis C virus (HCV) infection. The antibody was humanized by MRC Technology scientists, and originated in the laboratory of Prof. Arvind Patel, of the MRC-University of Glasgow Centre for Virus Research (CVR).

[Read More]